There are twin epidemics occurring in postmenopausal women, one being CHD and the other the metabolic syndrome (MS), between which there appears to be a connection.6-8 Metabolic risk factors such as elevated plasma triglyceride levels, decreased HDL cholesterol levels and glucose abnormalities have been suggested to portend a greater CHD risk in postmenopausal women,6,9 with the inflammatory markers, C reactive protein (CRP) and others appearing to modulate risk at all levels of the MS.10 This evidence concerns the gene CRP and metabolic syndrome.